Wafeu G. S., Lepage T. M., Campillo Jérémy, Efon-Ekangouo A., Nana-Djeunga H. C., Nzune-Toche N., Domche A., Sumo L., Njitchouang G. R., Tsasse M. A. F., Bopda J., Balog Y. A., Niamsi-Emalio Y., Mbickmen-Tchana S., Talla G. K., Kana Y. S. N., Messina F. D. M., Pion Sébastien, Kuesel A. C., Kamgno J., Boussinesq Michel, Chesnais Cédric. (2024). Safety and short-term efficacy of a single dose of 2 mg moxidectin in Loa loa-infected individuals : a double-blind, randomized ivermectin-controlled trial with ascending microfilarial densities. Open Forum Infectious Diseases, 11 (7), p. ofae240 [9 p.]. ISSN 2328-8957.
Titre du document
Safety and short-term efficacy of a single dose of 2 mg moxidectin in Loa loa-infected individuals : a double-blind, randomized ivermectin-controlled trial with ascending microfilarial densities
Année de publication
2024
Auteurs
Wafeu G. S., Lepage T. M., Campillo Jérémy, Efon-Ekangouo A., Nana-Djeunga H. C., Nzune-Toche N., Domche A., Sumo L., Njitchouang G. R., Tsasse M. A. F., Bopda J., Balog Y. A., Niamsi-Emalio Y., Mbickmen-Tchana S., Talla G. K., Kana Y. S. N., Messina F. D. M., Pion Sébastien, Kuesel A. C., Kamgno J., Boussinesq Michel, Chesnais Cédric
Source
Open Forum Infectious Diseases, 2024,
11 (7), p. ofae240 [9 p.] ISSN 2328-8957
Background In 2018, the US Food and Drug Administration approved the macrocylic lactone moxidectin (MOX) at 8 mg dosage for onchocerciasis treatment in individuals aged >= 12 years. Severe adverse reactions have occurred after ivermectin (IVM), also a macrocyclic lactone, in individuals with high Loa microfilarial density (MFD). This study compared the safety and efficacy of a 2 mg MOX dose and the standard 150 mu g/kg IVM dose in individuals with low L loa MFD.Methods A double-blind, randomized, ivermectin-controlled trial of a 2 mg moxidectin dose was conducted in Cameroon between May and July 2022. It enrolled 72 adult men with L loa MFD between 5 and 1000 microfilariae/mL. Outcomes were occurrence of adverse events (AEs) and L loa MFD reduction rate during the first month off treatment.Results No serious or severe AEs occurred among the 36 MOX- or the 36 IVM-treated individuals. Forty-nine AEs occurred in the MOX arm versus 59 AEs in the IVM arm. Grade 2 AE incidence was higher among IVM- than MOX-treated participants (38.5% and 14.3%, respectively, P = .043). Median MFD reduction rates were significantly higher after IVM than MOX at day 3 (70.2% vs 48.5%), day 7 (76.4% vs 50.0%), and day 30 (79.8% vs 48.1%).Conclusions A single 2 mg MOX dose is as safe as 150 mu g/kg IVM in patients with low L loa MFD. Further studies with higher MOX doses and in patients with higher MFD are warranted.Clinical Trials Registration NCT04049851.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
CAMEROUN
Localisation
Fonds IRD [F B010091098]
Identifiant IRD
fdi:010091098
